-
Premier League transfer windfall a lifeline for ailing French clubs
-
Kyrgios gets month ban for cocaine, enters treatment programme
-
Chile protesters see shades of Pinochet in new security plan
-
Colombian judge bans strikes on guerrillas if minors are present
-
Carreras reverts to fullback as Argentina change four for Australia Test
-
Khachanov shocks ailing Auger-Aliassime, Swiatek and Osaka advance at US Open
-
Wilson back to lead Australia as Kiss rotates team for Argentina
-
Lone juror blocking verdict in US mother's child murder trial: defense
-
Yen surges on new intervention talk, US stocks rally
-
'Kinda chic' - Williams sisters set to launch US Open doubles bid
-
Japan's Ueda fires Lille top of Ligue 1 on debut
-
Volkswagen says cutting 100,000 jobs by end of decade
-
Arsenal chief executive reveals 'dynasty' ambition
-
Russia slaps curfew on charity director over army criticism
-
Spanish PM says no 'solid proof' Morocco planned migrant rush
-
Ailing Auger-Aliassime upset by Khachanov at US Open
-
Iran war is not a war, US VP Vance says
-
Richarlison omitted from Tottenham's Premier League squad
-
Khachanov stuns third-seeded Auger-Aliassime in US Open second round
-
How El Nino is choking the Panama Canal
-
Bordeaux facing sixth-tier football after French federation upholds relegation
-
Hamilton drives his Ferrari dream at Monza
-
Stoic Verstappen looking beyond 'painful' Monza weekend
-
Senegal has an IMF loan, now what?
-
OpenAI begins rollout of new powerful AI model GPT-6 Astra
-
Auger-Aliassime upset by Khachanov at US Open
-
FIFA blasts UEFA 'smear campaign,' fights World Cup plan disclosures
-
Hugging Face, the French start-up that became AI's warehouse
-
Zelensky hopes to host US envoys in Kyiv in 'coming days'
-
World Cup winner Llorente retires from Spain team at 31
-
Martinelli joins Al-Hilal from Arsenal for reported £60 million
-
Osaka squeezes into US Open third round
-
Tesla's semi-autonomous driving could be adapted to EU norms: France
-
Apple faces £2 bn lawsuit in UK over app privacy feature
-
37 people die from fumes during oil pipeline theft in Nigeria: NGO
-
Former champ Swiatek eases into US Open third round
-
Ahead of elections, Israel tests West's patience on West Bank violence
-
DR Congo latest to promise moving Israel embassy to Jerusalem
-
Antonelli will obey Mercedes orders to help 'tow' teammate Russell
-
War criminal Mladic's body returns to Serbia with military honours
-
UK fintech Revolut gains conditional US banking licence
-
Pierre Cardin museum brings designer's futurist style to Venice
-
Mara sisters channel childhood energy for twins performance at Venice
-
Slovenian rookie Omrzel triumphs as Mas extends Vuelta lead
-
UN's Sudan probe says foreign fighters fuelling conflict
-
British, French leaders talk migrants, EU relations
-
Violence erupts at S.Africa anti-migrant protest
-
Heading for Ferrari's home race, Leclerc still dreams of world title
-
Nothing left: Nepal flood survivors face loss and uncertainty
-
Cafe at centre of Israel culture clash agrees to shut on Sabbath
Moderna to Present at Upcoming Conferences in March 2025
CAMBRIDGE, MA / ACCESS Newswire / February 25, 2025 / Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences:
TD Cowen 45th Annual Health Care Conference, on Wednesday, March 5th at 9:10am ET
Barclays 27th Annual Global Healthcare Conference, on Tuesday, March 11th at 1:30pm ET
A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website.
Webcast: investors.modernatx.com.
A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
[email protected]
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
T.Sanchez--AT